TiGenix NV (Euronext Brussels and NASDAQ: TIG), an advanced biopharmaceutical company focused on exploiting the anti-inflammatory properties of allogeneic, or donor-derived, stem cells to develop nove...
Oryzon is finishing an on going double - blind, placebo - controlled Phase 1 clinical trial in healthy volunteer s of its proprietary oral LSD1 - MAOB dual selective inhibitor ORY - 2001. The company ...
The scientific publication of international dissemination Annals of Cardiothoracic Surgery (ACS), dedicated to the field of cardiothoracic surgery, has released a scientific paper on clinical trial re...
Avizorex Pharma –an ophthalmology biotech company with offices at Barcelona Science Park (PCB)– announcesthe submission of a Clinical Trial Application (CTA) to the Spanish Competent Authority, re...
The European consortium CARE-MI has released the first results of its phase I/II clinical trial with cardiac stem cells for large myocardial infarction. At six months post-treatment, initial results i...
The results have demonstrated excellent drug efficacy for the treatment of amyloidosis, as it has been able to stabilize the 100% of protein transthyretin (TTR) present in plasma in all patients treat...